Total ginsenosides of ginseng stems and leaves veterinary grade API is a saponin-enriched fraction obtained from the aerial parts of Panax ginseng C.A. Meyer. The material is standardised for total ginsenoside content, typically expressed as the sum of ginsenosides Rg1, Re, Rb1, Rc, Rb2 and Rd by high-performance liquid chromatography. Downstream formulation is governed less by a universal monograph than by dosage-route-specific limits for residual solvent, pesticide, heavy metal and microbial burden. For feed use, the API is most often introduced into a premix or stock solution rather than direct addition to complete feed, because the active mass per metric ton of complete feed is small and the saponin fraction exhibits hygroscopicity and moderate aqueous foaming. The following application routes are limited to those for which published data, regulatory filings or production-scale equipment behaviour exist: swine feed premixes, poultry drinking-water granules, companion animal oral solid dosage forms, ruminant oral boluses and drenches, aquaculture extruded feed, and injectable screening. In each route, the addition ratio must be recalculated from the standardised total ginsenoside content of the input batch, not from raw material weight.

Swine Nursery Premix Inclusion Windows and Pellet-Conditioning Constraints

The most established downstream use of total ginsenosides of ginseng stems and leaves veterinary grade is incorporation into swine nursery and grower-finisher feed through a 1:100 or 1:200 premix. Compliance for this route falls under the feed hygiene and feed additive framework rather than the pharmaceutical code. In the European Union, the material may be placed on the market only where the appropriate feed additive category is authorised under Regulation (EC) No 1831/2003; in the United States, the premix must be manufactured in accordance with 21 CFR 507 preventive controls for animal food, and the ingredient must be acceptable under the AAFCO Official Publication. Sampling and sample preparation for content uniformity follow ISO 6497:2002, while routine analytical verification of total ginsenoside content should be conducted under an ISO/IEC 17025:2017-accredited method. Because the raw API is hygroscopic and prone to lumping at relative humidity above 60%, pre-blending with a moisture-scavenging carrier such as calcium silicate or fumed silica at 1.0–3.0 wt% of the premix is common before the main mixing step. Formulation addition ratio for a nursery complete feed target of 5–20 mg total ginsenosides per kilogram complete feed is calculated as follows: a standardised 20.0% total ginsenoside API requires 25–100 mg API per kilogram complete feed. In a 1:100 premix, this corresponds to 2.5–10.0 g API per kilogram premix. The lower bound is generally used for routine long-term administration; the upper bound is reserved for short-duration stress windows around weaning or vaccination.

Downstream production for pelleted feeds introduces a thermal conflict. Swine feed pelleting commonly operates with conditioner temperatures of 70–85°C and residence times of 20–45 seconds. Total ginsenosides in aqueous environment undergo progressive loss above 60°C; however, published recovery data through commercial pellet mills for this specific stem-leaf API are limited. Production-scale equipment behaviour indicates that unprotected ginsenoside premixes added before the conditioner can show batch-to-batch recovery drift when steam pressure fluctuates and when die frictional heat exceeds 80°C. The preferred process strategy is therefore post-pellet liquid application of a microencapsulated or oil-adsorbed fraction onto cooled pellets, or the use of low-temperature conditioner settings where the formula permits. If the premix must be added before pelleting, the premix carrier should include a hydrogenated vegetable oil coating and the mixer fill should be maintained at 55–65% of total volume in a horizontal ribbon mixer, with mixing time of 12–18 minutes at 25–30 rpm, followed by discharge through a 9.5 mm screen. Homogeneity verification should use ten sampling points with coefficient of variation <5.0% for total ginsenosides by HPLC after extraction. The terminal finished product types include nursery prestarter meal, pelleted grower-finisher feed, top-dress powder and a water-stable oral gel for spot administration. Operational boundary: do not combine with high-dose organic acids or molasses in the same premix without moisture protection, because acid hydrolysis of ginsenoside glycosidic bonds can occur during storage at moisture above 10%.

How Does Acidified Drinking Water Affect Granule Disintegration and Saponin Stability in Broiler Administration?

Poultry administration through drinking water is selected when feed intake is depressed during heat stress, coccidiosis vaccination or post-placement handling. The relevant compliance framework depends on the claim: a zootechnical feed additive in water requires authorisation under Regulation (EC) No 1831/2003; a veterinary medicinal claim requires national veterinary registration and GMP for veterinary medicinal products. Water-administration formulations are normally produced as water-soluble granules, effervescent tablets or soluble powders. The addition ratio for broilers is calculated from daily water consumption rather than body weight alone. For a target of 2–5 mg total ginsenosides per kg body weight per day in 1.5–2.0 kg broilers, the corresponding drinking-water concentration is ordinarily 0.01–0.03 g/L when water consumption is 150–200 mL per bird per day. For proportioner stock solutions at 1:100, this requires 1.0–3.0 g total ginsenosides per litre of stock solution; with a standardised 20.0% API, the API demand is 5.0–15.0 g per litre of stock solution. These values are arithmetic starting points and must be adjusted by water intake on the farm.

The critical process constraint in water-soluble granules is not granule formation itself but the interaction between hard water, acidic drinking water sanitizers and saponin solubility. Fluidised bed granulation with an inlet air temperature of 50–55°C and product temperature held at 35–40°C is used to limit thermal degradation. The granulated material is sieved to 20–60 mesh, and friability is controlled by a low-viscosity binder such as povidone K30 at 0.5–1.5 wt% of the dry blend. Field data from broiler operations show that chlorinated drinking water containing free chlorine at 0.5–1.0 mg/L does not fully eliminate the active fraction, but acidified water below pH 5.0 can accelerate the hydrolysis of ginsenoside glycosidic bonds during 24-hour standing in stock solution. The operational boundary is to prepare stock solutions not more than 12–18 hours before delivery and to avoid acidifiers such as citric acid at levels that lower pH below 5.0 in the same stock solution. Terminal finished product types include water-soluble granules, soluble powder in unit-dose sachets, and proportioner stock solution for automatic dosing.

In companion animal oral solid dosage forms, total ginsenosides of ginseng stems and leaves veterinary grade is incorporated into flavoured tablets, capsules and soft chews for stress-related appetite depression in dogs and cats. Compliance for non-medicated supplements in the United States falls under 21 CFR 507 as animal food, with label structure and ingredient definition governed by AAFCO; in markets where a therapeutic claim is made, the product becomes a veterinary medicinal product and requires registration under 21 CFR 210/211 or the corresponding national GMP. Addition ratio is usually derived from species-specific milligram-per-kilogram body weight ranges. For dogs, a target of 1–3 mg total ginsenosides per kg body weight per day is a conservative formulation starting point; a 10 kg dog therefore receives 10–30 mg total ginsenosides per day. With a 50.0% total ginsenoside extract, this corresponds to 20–60 mg extract per chew or tablet. For cats, the total ginsenoside load is typically reduced to 0.5–1.5 mg/kg per day because of feline sensitivity to saponin surfactancy, and the lower bound is used for multi-day administration.

Direct compression is feasible only when the API is spray-dried onto a coprocessed carbohydrate carrier; otherwise the high hygroscopicity of the powdered extract causes sticking at compression forces above 10 kN and tablet hardness fluctuation outside 5–8 kp. Wet granulation with isopropyl alcohol or ethanol-based binder systems is used where aqueous granulation would initiate foaming and particle agglomeration. For capsules, the granulate is dried to a loss on drying of 3.0–5.0% and filled into hydroxypropyl methylcellulose capsules using a tamping pin machine with fill weight variation controlled to <5.0%. Disintegration testing follows USP <2040>; for tablets, a disintegration time of <30 minutes in 0.1 M hydrochloric acid is used as a release specification. The terminal finished product types are scored tablets, two-piece capsules, soft chews and flavoured oral powders packed in stick packs. Operational boundary: avoid direct blending with hygroscopic liver hydrolysate in soft chew bases unless the moisture content of the base is below 8.0%, because free water accelerates ginsenoside hydrolysis and browning.

Controlling Rumen pH During Ginsenoside Oral Bolus Release

Ruminant application is directed primarily at transition dairy cows and receiving feedlot calves where feed intake suppression and immune stress overlap. The compliance route is feed additive or oral drench, depending on registration status and claim; feed use falls under Regulation (EC) No 1831/2003 for authorised zootechnical additives, or 21 CFR 507 for animal food in the United States. Oral drench products, if presented as veterinary medicines, must be manufactured under 21 CFR 211 or EU GMP Part 2 and tested for microbial limits. The addition ratio for a transition cow oral drench is commonly expressed on a per-head basis rather than per-kilogram body weight. Published data on ginsenoside efficacy in ruminants remain limited; formulators should treat a total ginsenoside dose of 0.2–0.5 g per head per day in a 100 mL drench as an exploratory range, not a validated pharmacopoeial dose. For feedlot receiving rations, a complete feed concentration of 5–15 mg total ginsenosides per kilogram dry matter is used as a formulation starting point, assuming standardised 20.0% API. With a 1:100 premix, this corresponds to 2.5–7.5 g API per kilogram premix.

The main process conflict in ruminant oral bolus manufacture is ruminal degradation. Ginsenoside saponins can be hydrolysed by rumen microbial beta-glucosidases, and unprotected powder inserted into a soluble gelatin capsule may release as a bolus pulse before passage. Production-scale approaches include high-load oral drenches with propylene glycol and poloxamer 188 as wetting and defoaming agents, or matrix boluses with hydrogenated castor oil and high-density weighting agents to delay release in the rumen. High-shear mixing is used at 500–1,500 rpm with a jacket temperature below 40°C to prevent foam generation and ginsenoside aggregation. The terminal finished product types are oral drench, gelatin capsule, rumen bolus, and mineral premix for transition cow total mixed ration addition. Operational boundary: the API should not be pre-mixed with alkaline rumen buffer packs above pH 8.5 for more than 24 hours, because ginsenoside hydrolysis accelerates under alkaline conditions.

Aquaculture feed application of total ginsenosides of ginseng stems and leaves veterinary grade is concentrated in finfish and shrimp diets where handling stress, transport and viral disease pressure require immune-modulating support. This route is regulated as aquafeed or feed additive, not as a veterinary medicine, so compliance is anchored to ISO 22000:2018 for food safety management, ISO 6497:2002 for sampling, and the AAFCO Official Publication or local aquafeed ingredient registry for ingredient acceptance. The addition ratio differs between finfish and shrimp because of leaching loss in aquatic media. For finfish practical diets, a target of 10–30 mg total ginsenosides per kilogram dry feed is used as a starting point for stress-period administration. For shrimp, the concentration is generally reduced to 5–15 mg total ginsenosides per kilogram dry feed because the feed remains in pond water for several hours and water elution of unencapsulated saponin can occur. With a standardised 20.0% API, these targets correspond to 50–150 mg API per kilogram finfish feed and 25–75 mg API per kilogram shrimp feed.

The production process must account for severe heat exposure in extruded aquafeed. Twin-screw extrusion for floating fish feed typically uses preconditioner temperatures of 90–95°C and barrel temperatures above 120°C; unprotected addition of ginsenoside premix before extrusion would expose the active fraction to destructive thermal and mechanical conditions. The preferred manufacturing route is post-extrusion vacuum coating: the API is dispersed in fish oil or lecithin at 0.5–2.0 wt% of the pellet mass and applied in a vacuum coater at 0.2–0.6 bar and oil temperature of 40–50°C. This reduces surface dusting and limits contact with barrel shear. For sinking shrimp pellets, a low-temperature pellet press or cold pelleted diet is preferred, with pellet water stability measured to remain above 80% after 1 hour in seawater. Terminal finished product types include extruded floating finfish feed, sinking shrimp pellet, top-dress oil emulsion, and hatchery enrichment premix. Operational boundary: the API should not be acidified with citric acid in oil-coating suspensions below pH 4.0, because low pH can initiate saponin hydrolysis before pellet storage.

When Parenteral Grade Material Is Evaluated for Injectable Immunomodulation

Injectable use of total ginsenosides of ginseng stems and leaves veterinary grade is the most restrictive downstream route and is included here because the API is specified for injection-compatible quality in some supplier data. Compliance is pharmaceutical rather than feed: the finished injectable must meet sterility, endotoxin, particulate matter and container-closure requirements under USP <1>, USP <71>, USP <85> and USP <788>, and the manufacturing facility must operate under 21 CFR 210/211 or EU GMP Annex 2 for sterile medicinal products. The formulation addition ratio is not established as a clinical dose in harmonised veterinary pharmacopoeias. Published data for this specific extract in injectable veterinary products are limited; therefore, screening formulations are confined to forced-degradation and local-tolerability bracketing studies. A starting solubility and stability screening range of 0.01–0.1 g total ginsenosides per 100 mL is used in aqueous solvent systems containing 5–20% propylene glycol and 0.1–0.5% polysorbate 80, but this range is not a dosing recommendation. Without membrane protection, free saponins can cause concentration-dependent hemolysis, so the development program must include in vitro erythrocyte lysis screening before any injection study.

Production process for a sterile solution follows aseptic filling rather than terminal sterilisation when the saponin fraction shows pH-dependent hydrolysis and foaming. The API is dissolved in water for injection under vacuum, adjusted to pH 5.0–6.5, clarified through a 0.45 µm prefilter, and sterilising filtered through a 0.22 µm polyethersulfone membrane. Terminal sterilisation by autoclaving at 121°C for 15 minutes is not recommended unless forced-degradation data demonstrate total ginsenoside recovery above 95.0%, because steam sterilisation can hydrolyse labile glycosidic bonds and generate visible particulate matter. Lyophilised powder for injection is an alternative terminal format when the active fraction is protected by cyclodextrin or mannitol-based bulking agents. The terminal finished product types are injectable solution, sterile lyophilised powder for reconstitution, and pre-filled syringe formulation for investigational use. Operational boundary: avoid combination with calcium-containing diluents because saponin–calcium interaction can produce insoluble aggregates; avoid pH below 4.0 in the final solution because acyl migration and hydrolysis are accelerated under acidic conditions.